Success Metrics

Clinical Success Rate
81.3%

Based on 13 completed trials

Completion Rate
81%(13/16)
Active Trials
0(0%)
Results Posted
46%(6 trials)
Terminated
3(16%)

Phase Distribution

Ph phase_1
5
26%
Ph phase_2
5
26%
Ph phase_3
3
16%
Ph phase_4
2
11%
Ph not_applicable
4
21%

Phase Distribution

5

Early Stage

5

Mid Stage

5

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
5(26.3%)
Phase 2Efficacy & side effects
5(26.3%)
Phase 3Large-scale testing
3(15.8%)
Phase 4Post-market surveillance
2(10.5%)
N/ANon-phased studies
4(21.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.3%

13 of 16 finished

Non-Completion Rate

18.8%

3 ended early

Currently Active

0

trials recruiting

Total Trials

19

all time

Status Distribution
Completed(13)
Terminated(3)
Other(3)

Detailed Status

Completed13
Terminated3
unknown3

Development Timeline

Analytics

Development Status

Total Trials
19
Active
0
Success Rate
81.3%
Most Advanced
Phase 4

Trials by Phase

Phase 15 (26.3%)
Phase 25 (26.3%)
Phase 33 (15.8%)
Phase 42 (10.5%)
N/A4 (21.1%)

Trials by Status

completed1368%
terminated316%
unknown316%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT00873275Phase 1

Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

Completed
NCT00909610Phase 1

Ursodiol Tablets 500 mg Under Fasting Conditions

Completed
NCT00909753Phase 1

Ursodiol 500 mg Tablets Under Fed Conditions

Completed
NCT01505569Not Applicable

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Completed
NCT02748616Phase 4

C. Difficile and Ursodiol

Completed
NCT00706381Phase 3

Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)

Completed
NCT02033876Phase 2

Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin

Completed
NCT02319629Not Applicable

Preventive Therapy With Ursodiol to Reduce the Incidence of Gallstones Formation in Patients After Bariatric Surgery

Unknown
NCT01097304Phase 2

Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia

Completed
NCT02385032Phase 1

Comparative Bioavailability Study of UDCA

Completed
NCT00004441Not Applicable

Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis

Completed
NCT00004442Not Applicable

Study of Bile Acids in Patients With Peroxisomal Disorders

Terminated
NCT00846963Phase 2

Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates

Completed
NCT00062023Phase 2

Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer

Terminated
NCT00514774Phase 1

Ursodiol in Huntington's Disease

Unknown
NCT00004784Phase 3

Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis

Completed
NCT00004315Phase 2

Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease

Unknown
NCT00004748Phase 3

Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis

Completed
NCT00042549Phase 4

Lithotripsy for the Treatment of Gallstones

Terminated

All 19 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
19